Sanofi “Bone cancer cure” development stopped
(medical pharmaceutical news)
Sanofi stopped all clinical trials and approval process of Fedratinib for rare bone cancer due to safety issue.
This decision was made due to the reports of side effects on the disabled Wernicke’s encephalopathy in the r...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
